Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing by Evidente, Virgilio Gerald H. & Pappert, Eric J.
Articles
Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing
Virgilio Gerald H. Evidente
1*
& Eric J. Pappert
2
1Movement Disorders Center of Arizona, Scottsdale, AZ, USA, 2Merz North America, Inc., Greensboro, NC, USA
Abstract
The first-line treatment for cervical dystonia (CD) is botulinum toxin type A (BoNT-A), which has been established as a highly effective and well-tolerated therapy.
However, this treatment is also complex and challenging to apply in clinical practice. Approximately 20% of patients discontinue therapy due to treatment failure,
adverse effects, and other reasons. In addition, expert consensus recommendations are lacking to guide physicians in the optimal use of BoNT-A for CD. Among the
issues still to be clarified is the optimal dosing frequency. The generally accepted standard for intervals between BoNT-A injections is >12 weeks; however, this
standard is based primarily on the methodology of pivotal trials for the BoNT-A products, rather than on evidence that it is optimal in comparison to other intervals.
While some retrospective, observational studies of BoNT-A used in clinical practice appear to support the use of >12-week dosing intervals, it is often unclear in
these studies how the need for reinjection was determined. In contrast, a prospective dose-ranging trial in which patients were allowed to request reinjection as early
as 8 weeks showed that about half of patients receiving abobotulinumtoxinA, at the currently recommended initial dose of 500 U, requested reinjection at 8 weeks.
Moreover, results from an open-label, 68-week extension phase of the pivotal trial of incobotulinumtoxinA showed that 47.1% of patients had received reinjection at
#12 weeks. Ongoing studies, such as the Cervical Dystonia Patient Registry for Observation of BOTOXH Efficacy (CD PROBE), may help clarify this question of
optimal dosing intervals for BoNT-A in CD.
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Introduction
Cervical dystonia (CD) is a movement disorder clinically character-
ized by involuntary contractions of cervical muscles, which cause
abnormal head movements and postures, often associated with head
tremor and chronic pain.1,2 Classifications of CD include torticollis
(turning or rotation of the head towards one side); laterocollis (tilting of
the head towards one side); anterocollis (head and neck flexion), and
retrocollis (head and neck extension) or a combination of these
movements.1,3 CD is the most common of the focal dystonias, which
include blepharospasm and writer’s cramp.4 Prevalence estimates for
CD in the general population have varied widely, from 0.006% from a
clinic-based study in eight European countries,4 to 0.4% in the USA,
based on a consumer database survey.5 The symptoms and burden of
CD may severely impair quality of life (QOL) and lead to social and
occupational disability.6–9 Although the etiology of CD remains
unknown, it is physiologically characterized by a deficiency of cortical
motor inhibition, which is associated with abnormalities in the motor
circuit involving the sensorimotor cortex, basal ganglia, and
cerebellum.10–13
Injection of botulinum toxin (BoNT) is the recommended first-
line treatment for CD, based primarily on data from seven
randomized, controlled, Class I clinical trials in which it was shown
to be highly effective and well tolerated.14–16 Use of BoNT type A
(BoNT-A) is the preferred treatment while BoNT type B (BoNT-B)
is recommended if there is resistance to BoNT-A.15 BoNT
formulations approved by the US Food and Drug Administration
for CD have been available to clinicians in the USA since 2000.17
These agents include three types of BoNT-A—onabotulinumtoxinA
(BOTOXH), abobotulinumtoxinA (DysportH), and incobotulinum-
toxinA (XeominH)—and one BoNT-B, rimabotulinumtoxinB
(Myobloc/Neurobloc).15 These four agents differ significantly with
regard to manufacturing, including complexity and purity, potency,
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and dosing; the potency units of these products are specific to each
and considered non-interchangeable.15,16
BoNT relieves CD symptoms by inhibiting the presynaptic release
of acetylcholine from peripheral terminals of motor neurons, causing
temporary denervation and muscle weakness lasting typically about 3
months.17 The clinical application of BoNT injection is both a science
and an art, requiring highly individualized treatment.3 There is often a
delicate balance to be found between achieving optimal efficacy and
avoiding adverse events (AEs), such as dysphagia, and occurrence of
primary or secondary non-response.3,16,18,19 Major factors to consider
in BoNT treatment include the number and selection of neck and
adjacent muscles to inject, the amount (dose) of toxin to use, and the
length of intervals of dosing (reinjection).20,21
However, few data on optimal use of BoNT for CD or expert
consensus recommendations are available to guide physicians in
consideration of these factors. Although this treatment for CD has
been used in clinical practice and studied for more than 25 years, the
variability of CD symptomatology and other factors such as
comorbidities and concomitant medications make it difficult to draw
general treatment schemas from clinical trial data.21 Moreover, many
technical questions regarding administration of BoNT treatment, such
as optimal dosing, dilution ratios, number of injection sites, dosing
intervals, and targeting procedure are inadequately studied to support
clear and detailed recommendations.21,22 Outcomes measurement in
CD has also been controversial and continues to evolve.21,23,24
Therefore, important questions remain regarding various aspects of
the optimal clinical application of BoNT for CD.21,24 This review will
focus on the question of optimal dosing intervals for repeat injections
using BoNT-A formulations.
Challenges in BoNT treatment for CD
Reviews of BoNT treatment for CD suggest that 70–90% of patients
with CD derive symptomatic benefit from BoNT with at least one
injection.16,21,24 However, approximately 20% of patients who receive
at least one injection discontinue long-term BoNT treatment, most
commonly because of treatment failure.22 BoNT treatment failure can
be described as any situation in which the patient, the physician, or
both are dissatisfied with the treatment outcome, such as primary or
secondary non-response (i.e., lack of efficacy), or intolerable adverse
events (AEs).25 Primary non-response has been defined as no response
following the first or any subsequent injection.25 Secondary non-
response may be described as at least two successful injections
characterized by clinical improvement and/or atrophy of injected
muscles, and/or typical AEs followed by at least two unsuccessful
injections in a row without patient improvement, no typical AEs, and
with or without evaluation for immunoresistance.25 The most common
BoNT treatment-related AEs leading to discontinuation are dysphagia
and neck weakness.22,26,27 In addition, discontinuations may occur
because of remission and significant improvement, or simply
inconvenience and other non-medical issues.26,28,29 Some patients
may also develop unacceptable weakness without significant benefits
even if all identifiable factors are optimal (i.e., they cannot be
adequately treated with BoNT).
An 8-year study (October 1988 to December 1995) in 616 clinic CD
patients who had received at least one injection of abobo-
tulinumtoxinA found that 126 (20.5%) patients had discontinued for
various reasons, including primary non-response in 33 (5.4%) patients,
and secondary non-response in 17 (4.8% of 357 patients who received
at least six injections); 27 (4.4%) patients in the total cohort
discontinued because of AEs, the most frequently named being
dysphagia (Table 1).26 Among the 17 secondary non-responders, at
least one antibody test detected neutralizing serum antibodies in nine
patients with an average age of onset of symptoms at 30 years. The
non-responders to BoNT-A had received significantly higher units per
injection, a greater rate of booster injections (defined as injections
administered within 6 weeks following the previous injection), and
shorter intervals of repeat injection intervals than responders to
treatment. This may reflect increased dose after non-response first
appears. In this study, only a few characteristics were statistically
significantly different and non-responders with antibodies were treated
at a younger age than non-responders without antibodies. The
difference in detection of antibody between non-responders may be
due to younger patients being more likely to develop neutralizing
antibodies than older patients (Table 2).26 A similar 10-year retro-
spective analysis (January 1990 to December 1999) of 106 clinic
patients with CD treated with onabotulinumtoxinA found that 63% of
patients at 5 years were experiencing sustained benefit from the
treatment, while 20 (18.9%) discontinued because of either primary
non-response (11; 10.4%) or secondary non-response (nine; 8.5%)
(Table 1).28 Only three (2.8%) patients had discontinued because of
AEs. Although reported to occur in 5.4%26 and 10.4%28 of CD
patients, primary non-response is very rare and is usually thought to be
due to inadequate dose, injection of inappropriate muscles, inap-
propriate technique, or prior immunization against BoNT. One of the
most common reasons for failure to return for treatment is
discontinuation due to relocation or a change to another treatment
center.
Another trial followed 100 consecutive clinic patients with CD over
a 10–12-year period after they had been initially treated with
abobotulinumtoxinA.29 Of the 90 evaluable patients (six were lost to
follow-up and four had died), 57 (63.3%) were still being treated with
BoNT-A and 36.7% had discontinued, more than half of whom had
dropped out after only one injection. Discontinuation because of non-
response occurred in four (4.4%) patients, including 1 (1.1%) with
primary non-response and three (3.3%) with secondary non-response,
while 11 (12.2%) discontinued because of AEs (Table 1); 18 (18.9%)
patients stopped treatment because of significant improvement or
inconvenience (costs, travel) of the treatment. In addition, a retro-
spective survey trial of 133 clinic patients with primary CD treated
with onabotulinumtoxinA over a 6-year period found that 104 (78.2%)
patients were continuing to receive the treatment, while 29 (21.8%)
had discontinued.27 Major patient-stated reasons for discontinuation
included ‘‘injections did not help symptoms’’ in 9.8% of patients, and
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AEs in 7.5%, including 3.0% for ‘‘swallowing problems,’’ and 4.5% for
excessive neck weakness. Of the patients who discontinued, 37.9% had
received only one or two injections.
Risk factors for BoNT-A discontinuation
Based on these and other studies, as well as clinical observation, a
number of possible risk factors for discontinuation because of
treatment failure and AEs have been identified.25,26 Factors that
could be associated with primary non-response include pseudodystonia
(incorrect diagnosis), wrong muscles injected or inaccessibility of the
implicated muscles, inadequate dosing, and unrealistic patient
expectations.25,26 In one study, for example, five patients who were
unresponsive to an initial injection of abobotulinumtoxinA became
responsive to a second injection at the same dose (500 U) given 6
weeks later, which appeared to suggest that the initial response was
associated with suboptimal administration technique rather than
patient factors.30 Secondary non-response may also be associated with
injection of the wrong muscles or inadequate dosing.31,32 Other
potential risk factors for secondary non-response, or patient perception
of non-response, include immunoresistance; patient depression or
stress; changes in the pattern of neck muscle activity, and too high
patient expectation (as the patient may have noticed the greatest
improvement with the initial injection compared to baseline).25,27,32
Reviews have indicated that AEs associated with BoNT treatment,
which typically include dysphagia, neck weakness, dry mouth,
dysphonia, and injection site pain, are generally transient and either
mild to moderate or intermittent.16,22,33,34 However, severe treatment-
related AEs may develop on rare occasions.16 Patients with smaller
neck muscle mass and those requiring bilateral injections into the
sternocleidomastoid muscles may be at increased risk of dysphagia.
Particularly, injections in the lower two-thirds of the sternocleidomas-
toid muscles may increase the risk of dysphagia compared to injections
in the middle and superior portions of said muscle. Injections in the
posterior triangle of the neck (levator scapulae, scalenus medius) and
deep injections in the splenius capitus also may increase the risk of
dysphagia (unpublished data).35
The risk of immunoresistance leading to secondary non-response
has been a continuing concern associated with BoNT treatment for
CD since its inception.25,36 Reported frequency of immunoresistance
with BoNT-A treatment of CD patients, as documented by formation
of blocking antibodies, have varied, with reported rates of up to 17%,
particularly in the older studies that had utilized the older formulation
of onabotulinumtoxinA containing a much higher protein load of
25 ng of protein/100 U. In contrast, the currently used formulation of
onabotulinumtoxinA, which was introduced in 1999, only contains
5 ng of protein/100 U and has approximately a sixfold reduced
potential for immunogenicity compared to the original formula-
tion.32,37,38 This finding suggested that higher protein load of the
BoNT agent is a risk factor for antibody formation.37 The long-term
treatment risk of antibody formation in CD patients with current
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IncobotulinumtoxinA, the only BoNT product free of any complex-
ing proteins, has the lowest molecular weight (150 kDA) of the BoNT
agents.41,42 The absence of complexing proteins in incobotulinumtoxinA
may reduce the rate of antibody formation, as complexing proteins
have been reported to contribute to the risk of formation of non-
neutralizing antibodies against the BoNT-A.43,44 A report investigat-
ing the administration of the BoNT-B, rimabotulinumtoxinB, in four
separate clinical trials for the treatment of CD showed no correlation
between antibodies against the toxin and outcome of the treatments.
The study evaluated the efficacy, safety and immunogenicity of
rimabotulinumtoxinB using the Toronto Western Spasmodic
Torticollis Rating Scale (TWSTRS) total score, Subject Global
Assessment, monitoring of AEs, and mouse neutralizing antibody
(MNA) assay. The toxin was administered every 3 months, for periods
up to 6 years. Results from the study showed rimabotulinumtoxinB
was effective for the long-term treatment of CD, and there was no
correlation between results from the MNA assay and the outcome of
the treatments. The lack of correlation between results from the
MNA assay may originate from the nature of the investigation in
which results from four separate clinical trials were pooled.
Alternatively, it is possible the assays were not performed properly
or there was a marked placebo effect.45 While immunoresistance is
not the cause of all secondary non-response to BoNT-A treatment,
formation of antibodies has been observed in approximately 50% of
non-responders with CD.26,32
Other postulated risk factors for immunoresistance include higher
doses per treatment cycle, use of ‘‘booster injections’’ 2 to 3 weeks after
an initial injection, more frequent injections, and younger age at onset
of CD.26,32,36,37,46–48 The risk of immunoresistance has been cited in
expert reviews as one reason to avoid frequent reinjections, although
recommended minimal intervals between injections have ranged from
8 to 12 weeks.16,20 In addition, data indicate that immunoresistance
tends to occur between 1 and 4 years after initial treatment, with
declining incidence after such period.36,48 However, the identification
of risk factors for immunoresistance remains uncertain and complex
due to the inconsistency of data and the retrospective designs of studies
of non-response and immunoresistance.25 For example, it is sometimes
unclear whether greater frequency of injections occurred initially
because of non-response, or led to immunoresistance that caused the
non-response.
Current standards and practice of dosing frequency
In general, expert reviews of BoNT treatment for CD recommend
using the lowest effective dose at the longest dosing interval that
effectiveness can be maintained, which is widely considered to be
about 12 weeks for most patients.16,22,49,50 Although the product
Table 2. Characteristics of Secondary Non-responders and Responders from Retrospective Clinical Practice Study of BoNT-A Treatment for CD (total N53571)
Characteristic, median (range) Secondary Non-responders (n517) Responders (n5303) p-Value2
Ab+ (n59) Ab2 (n58)
Age at onset of symptoms, years 30 (13–51) 39 (28–55) 41 (8–50) 0.0073
Duration of symptoms, months
Before treatment 38 (19–121) 47 (12–192) 58 (2–426) n.d.
Before non-response 36 (20–53) 40 (29–72) – n.d.
MU per session 875 (400–1750) 820 (400–2000) 750 (150–2250) 0.00013
Cumulative dose (MU) 9000 (6455–12405) 9675 (8475–18050) 7430 (2700–22475) 0.083
Interval, days 91 (11–271) 91 (3–273) 105 (1–874) 0.00013
No. of injections 11 (7–14) 14 (9–22) 10.2¡3.2 n.d.
Booster4 4/96 injections (4.2%) 7/117 injections (5.9%) 41/3089 injections (1.3%) 0.053,5
Ab, Neutralizing Antibodies; BoNT-A, Botulinum Toxin Type A; CD, Cervical Dystonia; MU, Mouse Units.
Non-parametric statistical comparisons (two-tailed Mann–Whitney U tests: x2 only for the booster injections) were performed between the Ab+ group and the
responders group.
1Population included all clinic patients with cervical dystonia over a 7-year period who had received six or more botulinum toxin type A injections (54 patients
discontinued; secondary non-response was never seen before the sixth injection).
2For comparisons between Ab+ secondary non-responding and responding patients.
3Mann–Whitney U test (two-tailed).
4Booster injections defined as injections within 6 weeks following the previous injection.
5Fisher’s exact test for 262 tables.
Data were previously published by Kessler et al.26
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labeling for BoNT products supports this general guideline, the data
on which these recommendations are based is limited.
The labeling for onabotulinumtoxinA recommends a total dose not
to exceed 360 U administered every 12–16 weeks or at longer
intervals, with dosing tailored to the individual patient based on head
and neck position, localization of pain, muscle hypertrophy, patient
response, and AE history.51 This recommendation is based primarily
on the protocol of a pivotal, randomized, double-blind, placebo-
controlled phase 3 clinical trial.52 In this trial, conducted in the USA
and Canada (May 1995 to October 1997), 170 patients who had
previously been responsive to one open-label injection of onabotuli-
numtoxin-A for a 10-week period, but continued to exhibit a 20% or
greater deviation of head position from normal, were subsequently
administered one injection of onabotulinumtoxinA or placebo and
followed for another 10 weeks. There was up to 6 weeks between the
first and second injections. Subjects received a maximum dose of
BoNT-A of 360 U. This study used onabotulinumtoxinA containing
the original bulk of BoNT-A (formulation contained 25 ng of toxin per
100 U).52 OnabotulinumtoxinA treatment significantly improved
Cervical Dystonia Severity Scale scores, compared with placebo, at
weeks 2, 4, 6, 8, and 10; however, most patients had returned to
pretreatment status by 3 months after treatment.51
The product labeling for abobotulinumtoxinA recommends an
initial dose of 500 U, with repeat doses of 250 U to 1000 U as needed,
at intervals of 12–16 weeks or longer as necessary, based on return of
clinical symptoms.40 The abobotulinumtoxinA package insert (PI)
document specifies that retreatment should not occur at intervals of
less than 12 weeks.40 The recommendations for abobotulinumtoxinA
are primarily based on two phase 3, randomized, placebo-controlled
studies in CD patients.53,54 In both trials, the TWSTRS total score at
week 4, the primary endpoint, was significantly improved from
baseline in patients treated with abobotulinumtoxinA compared with
placebo. In the first trial (n580), about 75% of patients had been
previously treated with BoNT for CD, and these patients were
required to have had their last injection >16 weeks before study
entry.53 The mean (SD) duration of efficacy in responders to
abobotulinumtoxinA treatment, defined as the time until recurrence
of symptoms to within 10% of the baseline TWSTRS total score, was
22.8 (12.5) weeks, and the median (range) time was 18.5 (9–46)
weeks.53 The second trial (n5116) included an open-label extension
phase of up to 94 weeks, and including up to four repeat injections; the
mean follow-up was 51.9 weeks.54 In this trial, more than 80% of
patients had been previously treated with BoNT, with a minimum
interval of 16 weeks before study entry as in the first trial. Among
responders to abobotulinumtoxinA, the mean (range) interval between
the initial injection of the randomized, controlled trial and the first
open label reinjection was 14.4 (3.9–29.9) weeks and the mean (SD)
interval between treatments during the open-label phase ranged from
15.0 (5.6) to 17.1 (8.0) weeks.54
The PI document for incobotulinumtoxinA recommends an initial
dose of 120 U, with frequency of subsequent injections to be
determined by clinical response ‘‘but should generally be no more
frequent than every 12 weeks’’.35 This recommendation is primarily
based on a phase 3, randomized, double-blind, placebo-controlled, 20-
week, multicenter trial in 233 patients with CD in which the TWSTRS
severity score at week 4, the primary endpoint, was significantly
improved in patients administered either incobotulinumtoxinA 120 U
or 240 U, compared with placebo.35,55 Most of the patients in this trial
(61%) had been previously treated with onabotulinumtoxinA, and
their last injection was required to be>10 weeks prior to study entry.55
Following initial injection, reinjection was allowed at a minimum of 8
weeks, based on clinical need and/or a return to baseline of TWSTRS
total score to >20; however, the percentage of patients requiring
reinjection before the maximum 20-week follow up was not reported.
In summary, the generally recommended minimum interval
between repeat BoNT-A injections provided in product PIs is about
12 weeks. The onabotulinumtoxinA PI recommends administration
every 12–16 weeks or longer intervals, although noting that in the
pivotal clinical trial, most patients had ‘‘returned to pretreatment
status by 3 months post-treatment’’.51 The abobotulinumtoxinA PI
also recommends reinjection at intervals of 12–16 weeks or longer, but
further states that ‘‘retreatment should not occur in intervals of less
than 12 weeks’’.40 The incobotulinumtoxinA PI provides more flexible
guidance, stating that frequency of repeat treatments should be
determined by clinical response, although it should generally be no
more frequent than every 12 weeks.35 It is reasonable to speculate that
the differences in recommendations for frequency of dosing given by
the product labeling documents are based on differences in the designs
of the pivotal trials for each agent.
Studies of variable BoNT-A administration patterns
Apart from the BoNT-A pivotal trials, a number of studies in CD
patients have evaluated the duration of efficacy and treatment intervals
with BoNT-A agents. In one such study, 75 toxin-naı¨ve patients were
randomly assigned to double-blind treatment with placebo or total
doses of abobotulinumtoxinA 250 U, 500 U, or 1000 U for and
assessed at 2, 4, and 8 weeks.18 At week 8, need for reinjection was
assessed and treatment was unblinded, allowing for open-label follow-
up for determining duration of effect. Efficacy outcomes included the
modified Tsui scale, pain rating, and global patient and investigator
assessments for efficacy. This study found that duration of effect was
dose dependent, with an insignificantly greater mean improvement in
the modified Tsui score in the 1000 U dose group, compared to the
lower dose groups. In addition, about half of the patients in the 250 U
and 500 U dose groups, and 39% of patients in the 1000 U groups,
requested reinjection at 8 weeks. This study demonstrated dose
dependency of both duration of efficacy and risk of AEs.18 Moreover,
the high percentages of patients requesting reinjection with both the
500 U (currently recommended) and 1000 U doses would seem to
indicate that the recommendation of >12 weeks for dosing intervals
given in the abobotulinumtoxinA PI, and other BoNT-A products,
may not be optimal for all patients. In fact, a multi-national survey of
botulinum toxin injectors and patients who were receiving
onabotulinumtoxinA or abobotulinumtoxinA for CD indicated that
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55% of physicians and 70% of patients prefer shorter injection
intervals than those intervals actually received.56,57
A retrospective chart review study in 102 patients with CD who had
been under continuous care for 1 year and 10 months (January 1,
1998, to August 31, 1999) found that the mean duration of efficacy,
inferred to be the time between repeat injections, was a mean (range)
of 15.5 (12.2–24.3) weeks.58 Long-term patterns of onabotulinumto-
xinA treatment for CD were also evaluated in a retrospective survey
study in 133 patients over 6 years (also discussed above).58 In this
study, among patients who were continuing with the treatment after 6
years (n5104; 78.2%), the mean interval (SD) between treatments was
137.32 days or 19.62 weeks (90.43). Among those who had stopped the
treatment for a variety of reasons (n529; 21.8%), the mean interval
(SD) between treatments was significantly longer at 144.9 days or 20.7
weeks (192.73), p50.01. Most patients in this study also achieved a
stable dose and injection frequency in their BoNT treatment regi-
men.58 A prospective, open label study assessed dosing patterns in 326
patients with CD who had been treated with onabotulinumtoxinA for
a mean (range) 2.5 years (3.2 months to 4.2 years), primarily to assess
the incidence of immunogenicity.38 Patients received a median
(maximum) of nine (12) injections. The median treatment interval
from the initial injection to first repeat treatment was 92 days (or 13.1
weeks); over the maximum of 12 injections, the range of median
intervals was 86–96 days (or 12.2–13.7 weeks). Only four (1.2%) of the
326 patients developed antibodies as determined by mouse protection
assay, three of whom stopped responding clinically to the BoNT-A
treatment.
These studies appear to support the general recommendation that
BoNT-A injection intervals should be in the range of 12–16 weeks.
However, the retrospective studies do not clarify whether such a
regimen is optimal clinical practice because varying intervals are not
correlated with efficacy and tolerability outcomes, and it is unclear in
such studies whether the injection intervals chosen were determined by
the physician or patient, and whether they were arbitrary or
specifically determined by clinical need, i.e., return of symptoms.
Indeed, the randomized, double-blind, prospective, dose-finding study
of abobotulinumtoxinA, which allowed patients to request retreatment
based on their symptoms starting at 8 weeks, found that about half of
patients given the now-recommended dose of 500 U of abobotu-
linumtoxinA had requested retreatment at 8 weeks.18
Few studies have prospectively assessed dosing intervals and other
BoNT-A treatment factors in correlation with efficacy, tolerability, and
safety outcomes. Such an assessment was performed in an ad hoc
analysis of the extension phase of the pivotal, 20-week, randomized,
placebo-controlled study of incobotulinumtoxinA treatment, dosed at
120 U or 240 U, in 233 patients with CD (see above).55,59 This long-
term extension phase of open-label treatment continued for more than
1 year, including 48 weeks of treatment and 20 weeks of follow up.59
The extension phase protocol allowed for >6-week intervals between
injections, based on physician and patient discretion, but with the
requirement of a TWSTRS total score of >20 for retreatment, as in
the double-blind phase of the study. Of the patients participating in the
randomized, placebo-controlled trial, 214 completed the double-blind
phase and entered the extension phase.59 In a post hoc analysis of
dosing intervals, each patient who received two or more extension
phase injections was classified into one of three interval groups
according to their median injection interval: #10 weeks; .10 to #12
weeks; .12 to #14 weeks; or .14 weeks. Mean change in TWSTRS
total score across all injection sessions and incidence of AEs were then
analyzed by injection interval group.
During the extension phase, 191 (89%) patients received two or
more injections.59 One-third of patients participating in the extension
phase received re-injections at .14 weeks; the rest of the patients were
roughly equally divided between the intervals of #10 weeks (22.5%),
.10 to #12 weeks (24.6%); and .12 weeks to #14 weeks (19.4%).59
Notably, this showed that 47.1% of patients had received reinjections
at median intervals of #12 weeks, which is shorter than the standard
recommended interval for BoNT-A therapy for CD patients. Mean
doses received for both dose groups (120 U and 240 U) were similar
across all injection sections and interval groups.59 The mean changes
from baseline in TWSTRS total scores in each interval group showed
statistically significant improvements 4 weeks after each injection
(p,0.0001) (Figure 1).59 In addition, there were no statistically
significant differences in the overall occurrence of AEs between
interval groups (Table 3).59 Increased antibody production occurred in
three (1.3%) patients and had no correlation with dosing frequency
during the extension phase.
A prospective clinical study aimed at investigating the injection of
fixed doses of incobotulinumtoxinA at flexible intervals (6–20 weeks)
was recently conducted in patients with CD. In this study, patients
received up to six injections of incobotulinumtoxinA in two
treatments; a main period with treatment of 120 U, 240 U
incobotulinumtoxinA or placebo (214 patients), followed by sub-
sequent randomization to 120 U or 240 U during the extension
period (169 patients). Doses and intervals of incobotulinumtoxinA
injections were determined by physician assessment, using the
TWSTRS total score, upon patient request. As reported by
Evidente et al.,60 44.9% of patients received incobotulinumtoxinA
injections at intervals less than 12 weeks. Results from the study
showed treatment intervals of 6–7 weeks with incobotulinumtoxinA
were well tolerated and AE frequency was similar for injection
intervals ,12 weeks and >12 weeks with repeated injections of
incobotulinumtoxinA. The most frequent AEs were dysphagia and
neck pain.60 Brin et al.38 and Evidente et al.59 reported 1.2% and
1.3% of patients treated for CD with onabotulinumtoxinA or
incobotulinumtoxinA developed antibodies over treatment periods
of 4.2 years and over a year, respectively. Evidente et al.60 reported
incobotulinumtoxinA treatments were well tolerated for injection
intervals ,12 weeks and >12 weeks with repeated injections of
incobotulinumtoxinA. Hence, the likelihood of developing antibodies
for injection intervals whether ,12 weeks or >12 weeks with
repeated injections of incobotulinumtoxinA or BoNT-A should
remain low.
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Future studies
Other ongoing studies promise to provide further clinical data on
facets of optimal BoNT-A treatment practice for CD, including
injection intervals. Among them, the Cervical Dystonia Patient
Registry for Observation of BOTOXH Efficacy (CD PROBE) is a
prospective, multicenter, clinical registry in the US that is enrolling
patients with CD who are toxin-naı¨ve and/or new to physicians’
practices or had been in a clinical trial and received their last injection
>16 weeks prior to enrollment.21 Patients are followed over three
injection cycles of onabotulinumtoxinA with assessments at time of
injection and 4–6 weeks afterward. Data on patient demographics and
CD disease history, treatment, including dosing intervals, and efficacy
and safety/tolerability outcomes will be gathered and assessed. In this
open-label study, the frequency of injection is up to the physician.
Therefore, it is unlikely the study will provide useful data about
injection frequency. An interim report of physician-reported outcomes
for CD PROBE, including 499 enrolled patients, showed that the
mean (SD) interval between the first and second injections was 100.4
Figure 1. Mean (SD) Toronto Western Spasmodic Torticollis Rating Scale Total Score. Results at 4 weeks after each of five injection sessions. Error bars
represent SD. *p,0.001; p-value is a one-sample t-test of change in TWSTRS total score from the injection visit to the visit 4 weeks later (with no replacement of missing
data).
Table 3. Incidence of TEAEs by Interval Group (Pooled Data of Both Treatment Groups) in CD Patients Who Received >2 BoNT-A Injections
(incobotulinumtoxinA 120 U or 240 U) During the Open Label Extension Phase of a Randomized, Placebo-Controlled Trial
Interval Group Number Patients Incidence of TEAEs Comparison of Frequency of
TEAEs Between Interval
Groups
Total N5191 Total N5110
n (%) n (%)
#10 weeks 43 (22.5) 31 (72.1) NS
.10 to #12 weeks 47 (24.6) 22 (46.8) NS
.12 to #14 weeks 37 (19.4) 21 (56.8) NS
.14 weeks 64 (33.5) 36 (56.3) NS
NS, Not Significant; TEAE, Treatment Emergent Adverse Event.
Data were previously published by Evidente et al.59
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(22.9) days and 100.0 (22.3) days between the second and third
injections; however, the percentages of patients receiving injections at
,12 weeks or >12 weeks (,84 days) was not reported.61 The interim
data also showed that 96 (19.2%) patients had discontinued treatment,
while nine patients withdrew for lack of efficacy and nine because of
AEs, 55 of the patients were either lost to follow up or withdrew
consent. Hence, discontinuations continue to be a problem affecting
approximately 20% of patients receiving BoNT-A therapy.
Conclusions
Although the application of BoNT-A treatment for CD is a complex
and challenging procedure, there are few expert recommendations and
supporting clinical data to guide clinicians in optimizing this therapy.
With regard to dosing frequency, there is a generally accepted
standard of >12 weeks for BoNT-A injection intervals. However, this
standard is based primarily on previous methodology of pivotal clinical
trials for BoNT-A products, rather than clear evidence of its optimal
efficacy, safety, and tolerability. In addition, this standard has not been
assessed in comparison with alternative intervals. Some study data
suggest a subgroup of patients would prefer dosing more frequently
than every 12 weeks or longer; however, the risks and benefits of
shorter dosing intervals are not well studied. Ongoing studies such as
CD PROBE may help answer some of these questions.
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